Stem Cell Therapeutics Corp. Announces a Traumatic Brain Injury Presentation at National Neurotrauma Symposium 2011
July 12 2011 - 8:00AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the
"Company") announces the oral presentation of traumatic brain
injury (TBI) research at the National Neurotrauma Symposium (NNS
2011) in Hollywood, Florida on July 12th, 2011 at 11:45 am. The
oral presentation will be given by Dr. Ludmila Belayev of Louisiana
State University and is entitled, "A Novel Therapeutic Strategy For
Traumatic Brain Injury". This research abstract was submitted for
peer review, and invited to be presented as an oral presentation.
The TBI study was designed to demonstrate that, in a controlled
rodent model of fluid percussion injury, recovery of brain cellular
integrity and function after TBI was improved by SCT's NTx-428
regimen in the treated group compared to placebo. As hypothesized
prior to the initiation of this study, treatment with human
chorionic gonadotropin (hCG) and then erythropoietin (EPO)
administered 24 hours after moderate to severe TBI was observed to
significantly decrease brain matter loss and improve functional
recovery of symptoms. An unexpected and key new observation from
this study was a substantial and significant increase in cell count
number in the dentate gyrus region and specifically CA3 neuron
population. Importantly, cell populations within the dentate gyrus
and specifically CA neurons are thought to play a role in key
memory functions in animals and man. Accompanying the maintenance
of overall brain volume and these specific cell populations was a
robust and statistically significant behavioral improvement which
started after day 14 and that continued to improve beyond day
21.
In North America, moderate to severe TBI is a leading cause of
cognitive and physical disability, and in excess of 1.4 million
individuals suffer TBI each year. Of those, 300,000 individuals
suffer sufficiently severe injury to be hospitalized. Individuals
who present with moderate to severe neurological injuries often
have symptoms that may persist as lifelong disabilities and include
cognitive, speech, perceptual, memory, sensory, social-emotional or
motor deficits.
"The research presented today at this prestigious meeting of
leading neuroscientists shows, for the first time, the discovery
that treatment with a regimen of hCG, followed by EPO positively
impacts recovery of hippocampal neuron populations within the
dentate gyrus, a region of the brain, during recovery from moderate
to severe TBI. The hippocampus is an area widely accepted to play
an important role in memory function as well as spacial navigation.
Within the hippocampus the dentate gyrus and its accompanying CA3
neurons are one of the richest sources of stem cells in the brain."
said Dr. Allen Davidoff, Chief Scientific Officer for Stem Cell
Therapeutics Corp. "We are encouraged by the positive results in
this rodent model of moderate to severe brain injury and the
statistically significant recovery of CA neuron and dentate gyrus
cell populations. This animal experiment importantly suggests a new
avenue to explore in our ongoing human clinical TBI studies at the
Foothills Hospital & University of Calgary under the guidance
of Dr. David Zygun."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) developing and
commercializing drug-based therapies to treat central nervous
system diseases. SCT is a leader in the development of therapies
that utilize drugs to stimulate a patient's own resident stem
cells. The Company's programs aim to repair brain and nerve
function lost due to disease or injury. The Company's extensive
patent portfolio of owned and licensed intellectual property
supports the potential expansion into future clinical programs in
numerous neurological diseases such as stroke, traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO
403-245-5495 ext.226 adavidoff@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024